Shots:

• The approval is based on P-III PANORAMA study results assessing Eylea (q8w- q16w) vs sham in 402 patients with non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME)
• The P-III PANORAMA study results: improvement on DRSS score by ≥2‑step (80%-65% vs 15%); @q16w & @q8w- reduction in risk (85% & 88%); @q8w- improvement in diabetic retinopathy (80%) respectively
• Eylea (aflibercept- q8w & q16w) injection is a VEGF inhibitor- blocking the growth of new blood vessels- reduces vascular permeability in the eye by targeting VEGF-A & PLGF and has received FDA’s approval for multiple indications including wet age-related macular degeneration and DR with DME

Ref: Regeneron | Image: WCSA WORLD